Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer-relationship with venous thrombosis risk

Thrombosis Research

Volumn 132, Issue 5, 2013, Pages 627-634

  Abu Saadeh, Feras ^a   Norris, Lucy ^a   O'Toole, Sharon ^a   Mohamed, Bashir M ^a   Langhe, Ream ^a   O'Leary, John ^a   Gleeson, Noreen ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

clear cell carcinoma; Tissue factor; VTE

Indexed keywords

CA 125 ANTIGEN; MESSENGER RNA; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTIGEN RETRIEVAL; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTADENOMA; CYTOREDUCTIVE SURGERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK; SURVIVAL TIME; VEIN THROMBOSIS;

CLEAR CELL CARCINOMA; TISSUE FACTOR; VTE;

AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; RNA, MESSENGER; THROMBOPLASTIN; UP-REGULATION; VENOUS THROMBOSIS;

EID: 84886099738     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.09.016     Document Type: Article

References (31)

1. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 2000 809 815
2. J.W. Blom, J.P. Vanderschoot, M.J. Oostindier, S. Osanto, F.J. van der Meer, and F.R. Rosendaal Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study J Thromb Haemost 4 2006 529 535
3. N. Levitan, A. Dowlati, S.C. Remick, H.I. Tahsildar, L.D. Sivinski, and R. Beyth Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285 291
4. A.O. Rodriguez, T. Wun, H. Chew, H. Zhou, D. Harvey, and R.H. White Venous thromboembolism in ovarian cancer Gynecol Oncol 105 2007 784 790
5. M. De Cicco The prothrombotic state in cancer: pathogenic mechanisms Crit Rev Oncol Hematol 50 2004 187 196
6. J. Chen, A. Bierhaus, S. Schiekofer, M. Andrassy, B. Chen, and D.M. Stern Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis Thromb Haemost 86 2001 334 345
7. A.A. Khorana, S.A. Ahrendt, C.K. Ryan, C.W. Francis, R.H. Hruban, and Y.C. Hu Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer Clin Cancer Res 13 2007 2870 2875
8. R.T. Poon, C.P. Lau, J.W. Ho, W.C. Yu, S.T. Fan, and J. Wong Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma Clin Cancer Res 9 2003 5339 5345
9. T. Nakasaki, H. Wada, C. Shigemori, C. Miki, E.C. Gabazza, and T. Nobori Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer Am J Hematol 69 2002 247 254
10. S. Pecorelli, J.L. Benedet, W.T. Creasman, and J.H. Shepherd FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics Int J Gynaecol Obstet 65 1999 243 249
11. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402 408
12. H. ten Cate, and A. Falanga Overview of the postulated mechanisms linking cancer and thrombosis Pathophysiol Haemost Thromb 36 2008 122 130
13. A. Falanga, C.J. Tartari, and M. Marchetti Microparticles in tumor progression Thromb Res 129 Suppl. 1 2012 S132 S136
14. B. Furie, and B.C. Furie Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation Trends Mol Med Apr 2004 171 178
15. B. Shao, M.G. Wahrenbrock, L. Yao, T. David, S.R. Coughlin, and L. Xia Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome Blood 118 2011 4015 4023
16. A. Varki Trousseau's syndrome: multiple definitions and multiple mechanisms Blood 110 2007 1723 1729
17. W. Ruf, and B.M. Mueller Thrombin generation and the pathogenesis of cancer Semin Thromb Hemost 32 Suppl. 1 2006 61 68
18. K. Uno, S. Homma, T. Satoh, K. Nakanishi, D. Abe, and K. Matsumoto Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer Br J Cancer 29 Jan 2007 290 295
19. N. Yokota, S. Koizume, E. Miyagi, F. Hirahara, Y. Nakamura, and K. Kikuchi Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells Br J Cancer 101 Dec 15 2009 2023 2029
20. F.O. Recio, M.S. Piver, R.E. Hempling, and D.L. Driscoll Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy Cancer 78 1996 2157 2163
21. L.R. Duska, L. Garrett, M. Henretta, J.S. Ferriss, L. Lee, and N. Horowitz When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes Gynecol Oncol 116 2010 374 377
22. F.A. Saadeh, L. Norris, S. O'Toole, and N. Gleeson Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival Eur J Obstet Gynecol Reprod Biol 170 2013 214 218
23. A.A. Khorana, C.W. Francis, K.E. Menzies, J.G. Wang, O. Hyrien, and J. Hathcock Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer J Thromb Haemost 6 2008 1983 1985
24. J.I. Zwicker, H.A. Liebman, D. Neuberg, R. Lacroix, K.A. Bauer, and B.C. Furie Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy Clin Cancer Res 15 2009 6830 6840
25. J. Thaler, C. Ay, H. Weinstabl, D. Dunkler, R. Simanek, and R. Vormittag Circulating procoagulant microparticles in cancer patients Ann Hematol 90 2011 447 453
26. R. Lacroix, C. Judicone, P. Poncelet, S. Robert, L. Arnaud, and J. Sampol Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol J Thromb Haemost 10 2012 437 446
27. B. Stavik, M. Tinholt, M. Sletten, G. Skretting, P.M. Sandset, and N. Iversen TFPIalpha and TFPIbeta are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity J Hematol Oncol 6 2013 5
28. N.A. Zakai, P.L. Lutsey, A.R. Folsom, S.R. Heckbert, and M. Cushman Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology Thromb Haemost 104 2010 207 212
29. E.O. Maciel, G.F. Carvalhal, V.D. da Silva, E.L. Batista Jr., and B. Garicochea Increased tissue factor expression and poor nephroblastoma prognosis J Urol 182 2009 1594 1599
30. S. Regina, J.B. Valentin, S. Lachot, E. Lemarie, J. Rollin, and Y. Gruel Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN Clin Chem 55 2009 1834 1842
31. G. Patry, H. Hovington, H. Larue, F. Harel, Y. Fradet, and L. Lacombe Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer Int J Cancer 122 2008 1592 1597